MNKD Overview

MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Wall Street analysts forecast MNKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNKD is9.25 USD with a low forecast of 7.50 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MannKind Corp revenue for the last quarter amounts to 90.17M USD, increased 15.08

MannKind Corp. EPS for the last quarter amounts to -0.05 USD, decreased -225.00

MannKind Corp (MNKD) has 592 emplpoyees as of June 20 2026.

Today MNKD has the market capitalization of 1.22B USD.